Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Anthrax Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Anthrax Overview | 13 | 1 |
| Pipeline Products for Anthrax Comparative Analysis | 14 | 1 |
| Anthrax Therapeutics under Development by Companies | 15 | 2 |
| Anthrax Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Anthrax Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Anthrax Products under Development by Companies | 21 | 3 |
| Anthrax Products under Investigation by Universities/Institutes | 24 | 1 |
| Anthrax Companies Involved in Therapeutics Development | 25 | 28 |
| Aduro BioTech, Inc. | 25 | 1 |
| Altimmune, Inc. | 26 | 1 |
| Aphios Corporation | 27 | 1 |
| Aradigm Corporation | 28 | 1 |
| AtralCipan | 29 | 1 |
| Cellceutix Corporation | 30 | 1 |
| ContraFect Corporation | 31 | 1 |
| Dynavax Technologies Corporation | 32 | 1 |
| Emergent BioSolutions Inc. | 33 | 1 |
| GlaxoSmithKline Plc | 34 | 1 |
| Green Cross Corporation | 35 | 1 |
| Grifols, S.A. | 36 | 1 |
| Hawaii Biotech, Inc. | 37 | 1 |
| iBio, Inc. | 38 | 1 |
| Merck &Co., Inc. | 39 | 1 |
| Microbiotix, Inc. | 40 | 1 |
| NanoBio Corporation | 41 | 1 |
| PaxVax, Inc. | 42 | 1 |
| Pfenex Inc. | 43 | 1 |
| PharmAthene, Inc. | 44 | 1 |
| Planet Biotechnology Inc. | 45 | 1 |
| Protein Potential, LLC | 46 | 1 |
| ProThera Biologics, LLC. | 47 | 1 |
| Soligenix, Inc. | 48 | 1 |
| Syntiron LLC | 49 | 1 |
| Tetraphase Pharmaceuticals Inc. | 50 | 1 |
| United Therapeutics Corporation | 51 | 1 |
| VLP Biotech, Inc. | 52 | 1 |
| Anthrax Therapeutics Assessment | 53 | 10 |
| Assessment by Monotherapy Products | 53 | 1 |
| Assessment by Combination Products | 54 | 1 |
| Assessment by Target | 55 | 2 |
| Assessment by Mechanism of Action | 57 | 2 |
| Assessment by Route of Administration | 59 | 2 |
| Assessment by Molecule Type | 61 | 2 |
| Drug Profiles | 63 | 75 |
| anthrax (virus like particles) vaccine Drug Profile | 63 | 1 |
| anthrax + plague vaccine Drug Profile | 64 | 1 |
| anthrax vaccine Drug Profile | 65 | 2 |
| anthrax vaccine Drug Profile | 67 | 1 |
| anthrax vaccine Drug Profile | 68 | 1 |
| anthrax vaccine Drug Profile | 69 | 1 |
| anthrax vaccine Drug Profile | 70 | 1 |
| anthrax vaccine Drug Profile | 71 | 1 |
| anthrax vaccine Drug Profile | 72 | 1 |
| anthrax vaccine 2 Drug Profile | 73 | 2 |
| Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax Drug Profile | 75 | 1 |
| ARD-3100 Drug Profile | 76 | 4 |
| AV-7909 Drug Profile | 80 | 2 |
| CF-306 Drug Profile | 82 | 1 |
| CF-307 Drug Profile | 83 | 1 |
| CF-308 Drug Profile | 84 | 1 |
| ciprofloxacin hydrochloride Drug Profile | 85 | 1 |
| DPX-Anthrax Drug Profile | 86 | 2 |
| DV-230 Drug Profile | 88 | 1 |
| Epimerox Drug Profile | 89 | 1 |
| GC-1109 Drug Profile | 90 | 1 |
| GREANX Drug Profile | 91 | 1 |
| Human Antibody Based Vaccines Drug Profile | 92 | 2 |
| KKL-35 Drug Profile | 94 | 1 |
| Marinus Drug Profile | 95 | 1 |
| Monoclonal Antibody for Respiratory Anthrax Drug Profile | 96 | 1 |
| Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax Drug Profile | 97 | 1 |
| PBI-220 Drug Profile | 98 | 2 |
| Peptides to Disrupt Cell Membrane for Infectious Diseases Drug Profile | 100 | 1 |
| PMX-0196 Drug Profile | 101 | 1 |
| PMX-0243 Drug Profile | 102 | 1 |
| PMX-225 Drug Profile | 103 | 1 |
| PMX-231 Drug Profile | 104 | 1 |
| PMX-255 Drug Profile | 105 | 1 |
| PreviThrax Drug Profile | 106 | 2 |
| Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis Drug Profile | 108 | 1 |
| Px-563L Drug Profile | 109 | 2 |
| Px-563L Second Generation Drug Profile | 111 | 1 |
| raxibacumab Drug Profile | 112 | 1 |
| RC-100b Drug Profile | 113 | 1 |
| RiVax + SGX-204 Drug Profile | 114 | 1 |
| Small Molecule to Inhibit DNA Helicase for Infectious Diseases Drug Profile | 115 | 1 |
| Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia Drug Profile | 116 | 1 |
| Small Molecules for Anthrax Drug Profile | 117 | 1 |
| Small Molecules for Bacterial Infections Drug Profile | 118 | 1 |
| Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax Drug Profile | 119 | 1 |
| Small Molecules to Inhibit Lethal Factor for Anthrax Drug Profile | 120 | 2 |
| Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis Drug Profile | 122 | 1 |
| Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections Drug Profile | 123 | 1 |
| solithromycin Drug Profile | 124 | 12 |
| TP-271 Drug Profile | 136 | 2 |
| Anthrax Dormant Projects | 138 | 4 |
| Anthrax Discontinued Products | 142 | 1 |
| Anthrax Product Development Milestones | 143 | 10 |
| Featured News &Press Releases | 143 | 1 |
| Jun 22, 2016: U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of NuThrax Vaccines | 143 | 1 |
| Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting | 144 | 1 |
| Aug 17, 2015: Pfenex Awarded HHS Contract Valued At Up To $143.5 Million For The Advanced Development Of Next Generation Anthrax Vaccine | 145 | 1 |
| Mar 24, 2015: Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine | 145 | 1 |
| Mar 09, 2015: Pfenex Exercises Glide Contract Extension for Solid Dose Formulation of Recombinant Protective Antigen (rPA)-Based Anthrax Vaccine | 146 | 1 |
| Jan 28, 2015: Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines | 146 | 1 |
| Dec 29, 2014: Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data | 147 | 1 |
| Dec 22, 2014: Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L | 148 | 1 |
| Oct 21, 2014: Immunovaccine Demonstrates Protection Against Lethal Anthrax Challenge with Rapid Acting, Single Dose Vaccine | 148 | 1 |
| Sep 08, 2014: Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation Anthrax Vaccine | 149 | 1 |
| Apr 01, 2014: Immunovaccine and Pfenex Report Positive Results From Single Dose Anthrax Vaccine Studies | 149 | 1 |
| Dec 17, 2013: Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine | 150 | 1 |
| Dec 17, 2013: Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine | 151 | 1 |
| Nov 05, 2013: Pfenex Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine | 151 | 1 |
| Sep 19, 2013: GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment | 151 | 2 |
| Appendix | 153 | 2 |
| Methodology | 153 | 1 |
| Coverage | 153 | 1 |
| Secondary Research | 153 | 1 |
| Primary Research | 153 | 1 |
| Expert Panel Validation | 153 | 1 |
| Contact Us | 153 | 1 |
| Disclaimer | 154 | 1 |